

Page 2 of 18

22 October, 2004

- II. Claim 9, drawn to an immunoassay method, classified in class 436, subclass 528, for example.
- III. Claim 10, drawn to an immunoassay method comprising a polyclonal antibody response in an immunized animal, classified in class 436, subclass 74, for example.
- IV. Claim 11, drawn to an immunoassay method comprising a monoclonal antibody present in a hydridoma supernatant, classified in class 436, subclass 548, for example.
- V. Claims 12-15, drawn to an immunoassay method comprising a metal ion solution, classified in class 73, subclass 61.42, for example.
- VI. Claims 16 and 18-19, drawn to an immunoassay method comprising an aqueous extract of a solid sample, classified in class 435, subclass 962, for example.
- VII. Claims 17-19, drawn to an immunoassay method comprising a water sample, classified in class 435, subclass 7.1, for example.
- VIII. Claims 20-21, drawn to a test kit, classified in class 435, subclass 287.2, for example.

Page 3 of 18

22 October, 2004

The restriction is respectfully traversed on the ground that the methods and compositions of claims 1-21 do not differ substantively in function, mode of operation or effect, and are therefore, not patentably distinct.

- 5 It has been asserted that Claims 1-8 ("Invention I") and Claim 9 ("Invention II"), Claim 10 ("Invention III"), Claim 11 ("Invention IV"), Claims 12-15 ("Invention V"), Claims 16 and 18-19 ("Invention VI"), or Claims 17-19 ("Invention VII") are related as product and process of use. Further, it has been asserted that the inventions are distinct, in that the product can be used in a materially different process of using that product. In the instant case, it is asserted that Applicant's
- 10 chelate-fluorophore tracer composition can be used as a contrasting agent. Applicant does not disclose or teach that his chelate-fluorophore tracer compositions can be used in the manner asserted nor is the undisclosed use inherent in Applicant's chelate-fluorophore tracer composition. It is known that utility as a contrasting agent is not an inherent or predictable property of an organometallic. Further, lengthy and arduous experimentation is needed to show
- 15 that an organometallic is useful as a contrasting agent in that it has high stability, low toxicity, physiological tolerability, suitable pharmacokinetics, suitable biodistribution, and provides for positive imaging effect of an organ, tissue, or physiological feature, all of which are known to be characteristics and properties that are known to be required for a contrasting agent. For example, in the absence of lengthy and arduous experimentation, it is not known nor can it be predicted
- 20 whether an organometallic will exhibit toxicities such as release of a toxic free metal ion, such as iron, lead, or manganese; dissociatively release the potentially toxic organic ligand; or be converted physiologically to metabolites which are more toxic than the organometallic itself. Likewise, in the absence of lengthy and arduous experimentation, it is not known nor can it be predicted that an organometallic will exhibit the orientation, orbital placement, or electronic
- 25 interaction that is known to be required for utility as a contrasting agent. In view of the foregoing,

Page 4 of 18

22 October, 2004

Applicant respectfully submits that the assertion is improper and requests that the inventions be rejoined.

It has been asserted that Claims 1-8 ("Invention I") and Claims 20-21 ("Invention VIII") are related as subcombination and combination. It has been asserted that Claims 20-21 are a combination because a chelating agent and biological binding agent have separate patentable utility as a chelation therapeutic. Applicant does not disclose or teach that his chelate-fluorophore tracer compositions can be used in the manner asserted nor is the undisclosed use inherent in Applicant's chelate-fluorophore tracer compositions. It is known that utility as a chelation therapeutic requires that the chelation therapeutic be able to bind an unchelated metal ion. Applicant's chelate-fluorophore tracer compositions are not capable of binding an unchelated metal ion, since a metal "M" is already resident in, liganded to, and saturates all available chelation sites of the chelate-fluorophore tracer compositions of the present invention [page 18, lines 10-25, pages 19-25, and page 26, lines 1-15, and the general formulas disclosed in Figure 1], and are not able, therefore, to bind another unchelated metal ion. Further, Applicant does not disclose or teach that his chelate-fluorophore tracer compositions can be used as contrasting agents in the manner asserted, nor is the undisclosed use inherent in Applicant's chelate-fluorophore tracer composition. It is known that utility as a contrasting agent is not an inherent or predictable property of an organometallic, and lengthy and arduous experimentation is needed to show that an organometallic has high stability, low toxicity, physiological tolerability, suitable pharmacokinetics, suitable biodistribution, and provides for positive imaging effect of an organ, tissue, or physiological feature, all of which are known to be characteristics and properties that are required for a contrasting agent. Applicant respectfully submits that the assertion is improper and requests that Inventions I and VIII be rejoined.

Page 5 of 18

22 October, 2004

It has been asserted that Claim 9 ("Invention II") and Claim 10 ("Invention III") are patentably distinct because they are not disclosed as capable of use together and have different modes of operation, different functions, or different effects. In the instant case it has been asserted that the different inventions have different modes of operation, in that Claim 9 requires an aqueous solution thought to contain a biological binding agent and Claim 10 requires a polyclonal antibody response in an immunized animal and serum. It is known that the mode of operation of antibody agents is selective binding to a hapten, and it is further known that antibodies of a polyclonal nature may be obtained from animals immunized with the hapten or their sera. Applicant has discovered a method for fluorescence polarization screening of macromolecular biological binding agents that are present in the sera of immunized animals or in hybridoma supernatants and may be reactive to target metal chelates. Applicant's method is useful to characterize and track the response of the macromolecular biological binding antibody agents to target and non-target metal chelates for the purpose of identifying desirable antibody anti-chelates of the present invention, wherein the desired antibody anti-chelates are selectively responsive, more responsive or most responsive to target metal chelates and are non-responsive to non-target metal chelates, and wherein the antibody anti-chelates of the present invention further comprise polyclonal antibody anti-chelates [Section VI: page 26, lines 17-25, pages 27-30, and page 31, lines 1-10; and Section VII: page 31, lines 12-25, pages 32-34, and page 35, lines 1-15]. Applicant submits that his antibody anti-chelates and polyclonal antibody anti-chelates have the same mode of operation in that they bind selectively to target metal chelates. In view of the foregoing, Applicant respectfully requests rejoinder of inventions II and III.

It has been asserted that Claim 9 ("Invention II") and Claim 11 ("Invention IV") are patentably distinct because they are not disclosed as capable of use together and have different modes of operation, different functions, or different effects. In the instant case it has been asserted the different inventions have different modes of operation in that Claim 9 requires an aqueous

Page 6 of 18

22 October, 2004

solution thought to contain a biological binding agent and Claim 11 requires a monoclonal antibody in a hybridoma supernatant. It is known that the mode of operation of antibody agents is selective binding to a hapten, and it is further known that fusions discovered by monitoring of the expression of polyclonal antibodies in an animal species or the stage and timing of expression of polyclonal antibodies in an animal species may be used to produce monoclonal antibodies to the hapten. Applicant has discovered a method for fluorescence polarization screening of macromolecular biological binding antibody agents that is useful to characterize and track the response of macromolecular biological binding antibody agents that may be reactive to target metal chelates for the purpose of identifying desirable macromolecular biological antibodies (i.e., Applicant's anti-chelates) that are selectively responsive, more responsive and most responsive to target metal chelates and non-responsive to non-target metal chelates, wherein the antibody anti-chelates further comprise monoclonal antibody anti-chelates [page 26, lines 17-25, pages 27-30, and page 31, lines 1-10; and Section VII: page 31, lines 12-25, pages 32-34, and page 35, lines 1-15]. Applicant submits that his antibody anti-chelates and monoclonal antibody anti-chelates have the same mode of operation in that they bind selectively to target metal chelates. In view of the foregoing, Applicant respectfully requests rejoinder of inventions II and IV.

It has been asserted that Claim 9 ("Invention II") and Claims 12-15 ("Invention V") are patentably distinct in that they have different modes of operation and Claim 9 requires a non-target chelate-fluorophore tracer composition, while Claims 12-15 require a metal ion solution. It is known that the mode of operation of macromolecular biological binding antibody agents is selective binding to a hapten. Applicant has discovered antibody anti-chelates of the present invention that are selectively responsive to target metal chelates and are non-responsive to non-target metal chelates in an aqueous solution containing both target metal chelates and non-target metal chelates [page 26, lines 17-25, pages 27-30, and page 31, lines 1-10; and Section VII: page 31, lines 12-25, pages 32-34, and page 35, lines 1-15]. Applicant respectfully submits that the mode

Page 7 of 18

22 October, 2004

of operation of inventions II and V is the same and is selective binding of an antibody anti-chelate composition of his invention to target metal ion chelates that are present in an aqueous solution containing both target metal ion chelates and non-target metal ion chelates. In view of the foregoing, Applicant respectfully requests rejoinder of inventions II and V.

5

It has been asserted that Claim 9 ("Invention II") and Claims 16 and 18-19 ("Invention VI") are patentably distinct in that they have different modes of operation and Claim 9 requires a non-target chelate-fluorophore tracer composition, while Claims 16 and 18-19 require an aqueous extract of a solid sample. It is known that the mode of operation of antibody agents is selective binding to a hapten, and it is further known that antibodies of a polyclonal nature may be obtained from animals immunized with the hapten, and that fusions discovered by monitoring of the expression of polyclonal antibodies in an animal species or the stage and timing of expression of polyclonal antibodies in an animal species may be used to produce monoclonal antibodies to the hapten. Applicant has discovered antibody anti-chelates that are selectively responsive to target metal chelate compositions of the present invention and are non-responsive to non-target metal chelates that are present in an aqueous solutions containing both target metal ion chelates and non-target metal ion chelates [page 26, lines 17-25, pages 27-30, and page 31, lines 1-10; and Section VII: page 31, lines 12-25, pages 32-34, and page 35, lines 1-15]. Applicant has further disclosed that an aqueous solution containing both target metal ion chelates and non-target metal ion chelates is prepared by exposing a solid sample to a water solution [Example 5, page 46, lines 13-25, page 47, and page 48, lines 1-17]. Applicant respectfully submits that the mode of operation of both invention II and invention VI is the same and is selective binding of an antibody anti-chelate composition of his invention to a target metal chelate that is present in an aqueous solution containing both target metal chelates and non-target metal chelates. In view of the foregoing, Applicant respectfully requests rejoinder of inventions II and VI.

Page 8 of 18

22 October, 2004

It has been asserted that Claim 9 ("Invention II") and Claims 17-19 ("Invention VII") are patentably distinct in that they have different modes of operation and Claim 9 requires a non-target chelate-fluorophore tracer composition, while Claims 17-19 require a water sample. It is known that the mode of operation of antibody agents is selective binding to a hapten, and it is further known that antibodies of a polyclonal nature may be obtained from animals immunized with the hapten, and that fusions discovered by monitoring of the expression of polyclonal antibodies in an animal species or the stage and timing of expression of polyclonal antibodies in an animal species may be used to produce monoclonal antibodies to the hapten. Applicant has discovered antibody anti-chelates that are selectively responsive to target metal chelate compositions of the present invention and are non-responsive to non-target metal chelates that are present in water solutions containing both target metal ion chelates and non-target metal ion chelates [page 26, lines 17-25, pages 27-30, and page 31, lines 1-10; and Section VII: page 31, lines 12-25, pages 32-34, and page 35, lines 1-15]. Applicant respectfully submits that the mode of operation of both invention II and invention VII is the same and is selective binding of an antibody anti-chelate composition of his invention to a target metal chelate that is present in a water solution containing both target metal chelates and non-target metal chelates. In view of the foregoing, Applicant respectfully requests rejoinder of inventions II and VII.

It has been asserted that Claim 9 ("Invention II") and Claims 20-21 ("Invention VIII") are related as product and process of use. Similarly, it has been asserted that this same relationship applies to Claim 10 ("Invention III") and Claims 20-21 ("Invention VIII"), Claim 11 ("Invention IV") and Claims 20-21 ("Invention VIII"), Claims 12-15 ("Invention V") and Claims 20-21 ("Invention VIII"), Claims 16, and 18-19 ("Invention VI") and Claims 20-21 ("Invention VIII"), and Claims 17-19 ("Invention VII") and Claims 20-21 ("Invention VIII"), in that the inventions embodied in Claims 9, 10, 11, 12-15, 16-18-19, or 17-19 (the product, respectively) can be used as a contrasting agent. Applicant does not disclose or teach that his chelate-fluorophore tracer compositions can be used in the

Page 9 of 18

22 October, 2004

manner asserted nor is the undisclosed use inherent in Applicant's chelate-fluorophore tracer composition. It is known that utility as a contrasting agent is not an inherent or predictable property of an organometallic, and lengthy and arduous experimentation is needed to show that an organometallic has high stability, low toxicity, physiological tolerability, suitable pharmacokinetics, suitable biodistribution, and provides for positive imaging effect of an organ, tissue, or physiological feature, all of which are characteristics and properties that are known to be required for a contrasting agent. For example, in the absence of lengthy and arduous experimentation, it is not known nor can it be predicted whether an organometallic will exhibit toxicities such as release of a toxic free metal ion, such as iron, lead, or manganese; dissociatively release the potentially toxic organic ligand; or be converted physiologically to metabolites which are more toxic than the organometallic itself. Likewise, in the absence of lengthy and arduous experimentation, it is not known nor can it be predicted that an organometallic will exhibit the orientation, orbital placement, or electronic interaction that is known to be required for utility as a contrasting agent. In view of the foregoing, Applicant respectfully submits that the assertion is improper and requests that inventions II and VIII be rejoined.

It has been asserted that Claim 10 ("Invention III") and Claim 11 ("Invention IV") are patentably distinct in that they have different modes of operation in that Claim 10 requires a polyclonal antibody response in an immunized animal and serum, and Claim 11 requires a monoclonal antibody in a hybridoma supernatant. It is known that the mode of operation of antibody agents is selective binding to a hapten, and it is further known that antibodies of a polyclonal nature may be obtained from animals immunized with the hapten or their sera, and that fusions discovered by monitoring of the expression of polyclonal antibodies in an animal species or the stage and timing of expression of polyclonal antibodies in an animal species may be used to produce monoclonal antibodies to the hapten. Applicant has discovered a method for fluorescence polarization screening using target and non-target chelate-fluorophore compositions of the present invention



Page 10 of 18

22 October, 2004

that is useful to characterize and track the response of macromolecular biological binding antibody agents that may be reactive to metal chelates for the purpose of identifying macromolecular biological antibody anti-chelates of the present invention that are responsive, more responsive and most responsive to target metal chelate-fluorophore tracer compositions and are non-responsive to non-target metal chelate-fluorophore tracer compositions [page 26, lines 17-25; pages 27-30, and page 31, lines 1-10; and Section VII: page 31, lines 12-25, pages 32-34, and page 35, lines 1-15]. Applicant has further disclosed that useful macromolecular biological binding antibody anti-chelates of his invention further comprise polyclonal macromolecular biological binding antibodies that are selectively responsive to target metal chelate-fluorophore tracer compositions (in other words, polyclonal antibodies that are anti-chelates of the present invention) and monoclonal macromolecular biological binding antibodies that are selectively responsive to target metal chelate-fluorophore tracer compositions (i.e., monoclonal antibodies that are anti-chelates of the present invention). In both instances, Applicant submits that the mode of operation of inventions III and IV is the same and is selective binding of the antibody anti-chelates of the present invention to target metal chelates. In view of the foregoing, Applicant respectfully requests that inventions III and IV be rejoined.

It has been asserted that Claim 10 ("Invention III") and Claims 12-15 ("Invention V") are patentably distinct in that they have different modes of operation and Claim 10 requires a polyclonal antibody response in an immunized animal and serum and Claims 12-15 require a water sample. It is known that the mode of operation of antibody agents is selective binding to a hapten, and it is further known that antibodies of a polyclonal nature may be obtained from animals immunized with the hapten or their sera. Applicant has discovered fluorescence polarization assay methods wherein the binding of macromolecular biological antibody anti-chelates of the present invention that are selectively responsive, more responsive and most responsive to target metal chelates and non-responsive to non-target metal chelates is useful for

Page 11 of 18

22 October, 2004

the determination of target metal ions in water (aqueous) solution [page 26, lines 17-25, pages 27-30, and page 31, lines 1-10; and Section VII: page 31, lines 12-25, pages 32-34, and page 35, lines 1-15]. In invention III Applicant's method is used to identify and select polyclonal antibody anti-chelates of the present invention in an aqueous (water) solution and in invention V, Applicant's method is used to determine target metal ion chelates in a water solution. In both instances, Applicant submits that the mode of operation of both inventions III and V is the same and is selective binding of antibody anti-chelates of the present invention to target metal chelates that are in a water solution containing both target metal chelates and non-target metal chelates. In view of the foregoing, Applicant respectfully requests rejoinder of inventions III and V.

10

It has been asserted that Claim 10 ("Invention III") and Claims 16 and 18-19 ("Invention VI") are patentably distinct in that they have different modes of operation and Claim 10 requires a polyclonal antibody response in an immunized animal and serum, while Claims 16, 18-19 require an aqueous extract of a solid sample. It is known that the mode of operation of antibody agents is selective binding to a hapten, and it is further known that antibodies of a polyclonal nature may be obtained from animals immunized with the hapten or their sera. Applicant has discovered fluorescence polarization assay methods wherein the binding of polyclonal antibody anti-chelates of the present invention that are selectively responsive, more responsive and most responsive to target metal chelates and non-responsive to non-target metal chelates is useful for the determination of target metal ions in an aqueous solution [page 26, lines 17-25, pages 27-30, and page 31, lines 1-10; and Section VII: page 31, lines 12-25, pages 32-34, and page 35, lines 1-15]. Applicant has further shown that an aqueous solution of target metal chelates and non-target metal chelates is obtained by exposing a solid sample to water solution (i.e., by extracting the solid sample) and that the fluorescence polarization assay methods of the present invention may be applied to the aqueous extracts thereby obtained [Example 5, page 46, lines 13-25, page 47, and page 48, lines 1-17]. In both inventions III and VI, Applicant submits that the mode of

25

Page 12 of 18

22 October, 2004

operation is the same and is selective binding of antibody anti-chelates of the present invention to target metal chelates that are present in an aqueous (water) solution containing both target metal chelates and non-target metal chelates. In view of the foregoing, Applicant respectfully requests rejoinder of inventions III and VI.

5

It has been asserted that Claim 10 ("Invention III") and Claims 17-19 ("Invention VII") are patentably distinct in that they have different modes of operation in that Claim 10 requires a polyclonal antibody response in an immunized animal and serum, and Claims 17-19 require a water sample. It is known that the mode of operation of antibody agents is selective binding to a hapten, and it is further known that antibodies of a polyclonal nature may be obtained from animals immunized with the hapten or their sera. Applicant has discovered fluorescence polarization assay methods wherein the binding of polyclonal antibody anti-chelates of the present invention that are selectively responsive, more responsive and most responsive to target metal chelates and non-responsive to non-target metal chelates that are in a water solution is useful for the determination of target metal ion chelates in the water solution containing both target metal ion chelates and non-target metal ion chelates [page 26, lines 17-25, pages 27-30, and page 31, lines 1-10; and Section VII: page 31, lines 12-25; pages 32-34, and page 35, lines 1-15]. Applicant submits that the mode of operation of inventions III and VII is the same and is selective binding of antibody anti-chelates of the present invention to target metal chelates that are present in a water solution containing both target metal chelates and non-target metal chelates. In view of the foregoing, Applicant respectfully requests rejoinder of inventions III and VII.

It has been asserted that Claim 11 ("Invention IV") and Claims 12-15 ("Invention V") are patentably distinct in that they have different modes of operation and Claim 11 requires a monoclonal antibody in a hybridoma and Claims 12-15 require a metal ion solution. It is known

Page 13 of 18

22 October, 2004

that the mode of operation of antibody agents is selective binding to a hapten, and it is further known that fusions discovered by monitoring of the expression of polyclonal antibodies in an animal species or the stage and timing of expression of polyclonal antibodies in an animal species may be used to produce monoclonal antibodies to the hapten. Applicant has discovered

5 fluorescence polarization assay methods wherein the binding of monoclonal antibody anti-chelates of the present invention that are selectively responsive, more responsive and most responsive to target metal chelates and non-responsive to non-target metal chelates in an aqueous solution is useful for the determination of target metal ions in an aqueous solution [page 26, lines 17-25, pages 27-30, and page 31, lines 1-10; and Section VII: page 31, lines 12-25,

10 pages 32-34, and page 35, lines 1-15]. Applicant respectfully submits that the mode of operation of inventions IV and V is the same and is selective binding of antibody anti-chelates of the present invention to target metal chelates that are present in an aqueous (water) solution containing both target metal chelates and non-target metal chelates. In view of the foregoing, Applicant respectfully requests rejoinder of inventions IV and V.

15

It has been asserted that Claim 11 ("Invention IV") and Claims 16, 18-19 ("Invention VI") are patentably distinct in that they have different modes of operation in that Claim 11 requires a monoclonal antibody in a hybridoma supernatant, and Claims 16, 18-19 require an aqueous extract of a solid sample. It is known that the mode of operation of antibody agents is selective

20 binding to a hapten, and It is further known that fusions discovered by monitoring of the expression of polyclonal antibodies in an animal species or the stage and timing of expression of polyclonal antibodies in an animal species may be used to produce monoclonal antibodies to the hapten. Applicant has discovered fluorescence polarization assay methods wherein the binding of monoclonal antibody anti-chelates of the present invention that are selectively responsive, more

25 responsive and most responsive to target metal chelates and non-responsive to non-target metal chelates is useful for the determination of target metal ions in an aqueous solution [page 26, lines

Page 14 of 18

22 October, 2004

17-25, pages 27-30, and page 31, lines 1-10; and Section VII: page 31, lines 12-25, pages 32-34, and page 35, lines 1-15]. Applicant has further shown that an aqueous solution of target metal chelates and non-target metal chelates is obtained by exposing a solid sample to water solution (i.e., by aqueous extraction of the solid sample) and that the fluorescence polarization assay methods of the present invention may be applied to the aqueous extracts thereby obtained [Example 5, page 46, lines 13-25, page 47, and page 48, lines 1-17]. Applicant respectfully submits that the mode of operation of inventions III and VI is the same and is selective binding of antibody anti-chelates of the present invention to target metal chelates that are present in an aqueous (water) solution containing both target metal chelates and non-target metal chelates. In view of the foregoing, Applicant respectfully requests rejoinder of Inventions IV and VI.

It has been asserted that Claim 11 ("Invention IV") and Claims 17-19 ("Invention VII") are patentably distinct in that they have different modes of operation and Claim 10 requires a monoclonal antibody in a hybridoma supernatant, while Claims 17-19 require a water sample. It is known that macromolecular biological binding antibody agents are useful as affinity reagents for binding to a hapten, and it is further known that fusions discovered by monitoring of the expression of polyclonal antibodies in an animal species or the stage and timing of expression of polyclonal antibodies in an animal species may be used to produce monoclonal antibodies to the hapten. Applicant has discovered fluorescence polarization assay methods wherein the binding of monoclonal antibody anti-chelates of the present invention that are selectively responsive, more responsive and most responsive to target metal chelates and non-responsive to non-target metal chelates in a water solution is useful for the determination of target metal ions in the water solution [page 26, lines 17-25, pages 27-30, and page 31, lines 1-10; and Section VII: page 31, lines 12-25, pages 32-34, and page 35, lines 1-15]. Applicant respectfully submits that the mode of operation of inventions IV and VII is the same and is selective binding of monoclonal antibody anti-chelates of the present invention to target metal chelates that are present in water containing

Page 15 of 18

22 October, 2004

both target metal chelates and non-target metal chelates. In view of the foregoing, Applicant respectfully requests rejoinder of inventions IV and VII.

It has been asserted that Claims 12-15 ("Invention V") and Claims 16, 18-19 ("Invention VI") are patentably distinct in that they have different modes of operation in that Claims 12-15 require a metal ion solution, and Claims 16, 18-19 require an aqueous extract of a solid sample. In "Webster's New Collegiate Dictionary," a publication of the G. & C. Merriam Company, Springfield, MA, U.S.A., the term "aqueous" is defined as (a) of, relating to, or resembling water, or (b) made from, with, or by water [photocopy appended as page 18]. Applicant submits that an aqueous extract of a solid sample is a solution of metal ions in water that is obtained by exposing a solid sample to water, as he has disclosed in Section VII: page 31, lines 12-25, pages 32-34, and page 35, lines 1-15. Applicant submits that the mode of operation of inventions V and VI is the same and requires an aqueous (water) solution containing metal ions. In view of the foregoing, Applicant respectfully requests that inventions V and VI be rejoined.

It has been asserted that Claims 12-15 ("Invention V") and Claims 17-19 ("Invention VII") are patentably distinct in that they have different modes of operation in that Claims 12-15 require a composition of Claim 1 and Claims 17-19 require a composition of Claim 3. Applicant has discovered chelate-fluorophore tracer compositions comprising metal-chelated reagents having the general formula disclosed in Figure 1 and Claim 1, wherein m is 0 or 1. Applicant has further disclosed that when m is 1, he provides the chelate-fluorophore tracer compositions comprising metal-chelated reagents having the general formula that is disclosed in Claim 3. Thus, Applicant's chelate-fluorophore tracer compositions of Claim 3 are also embodied in Applicant's chelate-fluorophore tracer compositions of Claim 1, when m is 1. In view of the foregoing, Applicant respectfully requests that inventions V and VII be rejoined.

Page 16 of 18

22 October, 2004

It has been asserted that Claim 16, 18-19 ("Invention VI") and Claims 17-19 ("Invention VII") are patentably distinct in that they have different modes of operation and Claims 16, 18-19 require a aqueous extract of a solid sample, while Claims 17-19 require a water sample. In "Webster's New Collegiate Dictionary," a publication of the G. & C. Merriam Company, Springfield, MA, U.S.A.,

5 the term "aqueous" is defined as (a) of, relating to, or resembling water, or (b) made from, with, or by water [photocopy appended as page 18]. Applicant submits that an aqueous extract of a solid sample is a water sample that is obtained by the process of exposing a solid sample to water, as he has disclosed in Section VII: page 31, lines 12-25, pages 32-34, and page 35, lines 1-15. Applicant submits that the mode of operation of Inventions VI and VII is the same and requires an  
10 aqueous (water) solution containing metal ions. In view of the foregoing, Applicant respectfully requests that the inventions be rejoined.

Applicant elects for examination Claims 12-15 (Invention V) and all inventions that may be properly rejoined thereto. Applicant respectfully draws attention to his discovery of materials and  
15 methods for measuring target metal ion chelate: anti-chelate binding by fluorescence polarization immunoassay. In the present application, he has disclosed immunoassay methods that use measures of the fluorescent signal from plane-polarized light that is obtained after target metal ion anti-chelates are exposed to target metal ion chelates and non-target metal ion chelates in aqueous solution, wherein the target metal ion antibody anti-chelates of his invention selectively  
20 bind to target metal ion chelates and do not bind to non-target metal ion chelates. Further, he has disclosed immunoassay methods that use measures of the fluorescent signal from plane-polarized light that are obtained after antibodies are exposed to chelate-fluorophore tracer compositions of his invention and has shown that these methods are useful for identifying antibodies, either of a polyclonal or a monoclonal nature, that are selectively responsive to target  
25 metal ion chelates and bind thereto and non-responsive (and non-binding) to non-target metal ion chelates. He has disclosed that antibodies exhibiting selective responsiveness to target metal ion